

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 7th day of February, 2002.

By \_\_\_\_\_

*[Signature]*  
(Signature of person mailing)

ROY F. WALDRON

(Typed or printed name of person)



**RECEIVED**  
MAY 03 2002  
TECH CENTER 1600/2900

MAR 06 2002

**RECEIVED**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: R. S. Obach

APPLICATION NO.: 09/528,798 : Examiner: S. Jiang

FILING DATE: March 21, 2000 : Group Art Unit: 1617

TITLE: USE OF CYP2D6 INHIBITORS IN  
COMBINATION THERAPIES

Commissioner for Patents  
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

Transmitted herewith is [X] a Response and Amendment; [X] Petition for Extension of Time; in the above-identified application.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2) Claims Remaining After Amendment	(3)	(4) Highest Number Previously Paid For	(5) Present Extra	(6) Rate	Additional Fee
Total Claims	3*	minus	22 **	= 0	X \$18.00	0
Independent Claims	1*	minus	3 ***	= 0	X \$78.00	0
	<input type="checkbox"/> Multiple Dependent Claim(s) fee				\$260.00	0
					TOTAL=	0

\* If the entry in column 2 is less than the entry in column 4, write "0" in column 5.

\*\* If the "Highest No. Previously Paid for" is less than 20, write "20" in this space.

\*\*\* If the "Highest No. Previously Paid for" is less than 3, write "3" in this space.

No additional fee is required.

Patent Application  
Attorney Docket No. PC10244A

A Petition for Extension of Time for responding within three month(s) of the response date is also enclosed. The Commissioner is authorized to charge the fee pursuant to 37 C.F.R. § 1.17(a)(3) in the amount of \$ 920.00. Two copies of this paper are enclosed.


Please charge Deposit Account No. 16-1445 in the amount of \$ \_\_\_\_\_. Two copies of this paper are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Respectfully submitted,

Date:

2/1/2002

  
Roy F. Waldron  
Attorney for Applicants  
Reg. No. 42,208

Pfizer, Inc  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 733-5086